LONDON - There was a second and final rejection of the University of Wisconsin's infamous WARF human embryonic stem cell patent from the European Patent Organization (EPO) last week. (BioWorld International) Read More
No Abstract Assistant Managing EditorDanish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential €140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2 receptor agonist, ZP1846, in chemotherapy-induced diarrhea (CID).Under the terms, Zealand granted Helsinn worldwide rights to the compound, except for the Nordic countries, where Zealand retains marketing rights. Read More
